Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Hartung HP, Benedict RHB, Berger T, Bermel RA, Brochet B, Carroll WM, Freedman MS, Holmøy T, Karabudak R, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Wuerfel J, Clinch S, Kadner K, Kuenzel T, Kulyk I, Raposo C, Thanei GA, Killestein J. Hartung HP, et al. Among authors: nos c. Neurology. 2024 Dec 24;103(12):e210049. doi: 10.1212/WNL.0000000000210049. Epub 2024 Dec 3. Neurology. 2024. PMID: 39626127 Clinical Trial.
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Ross AP, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Hartung HP, et al. Among authors: nos c. Mult Scler Relat Disord. 2020 Nov;46:102492. doi: 10.1016/j.msard.2020.102492. Epub 2020 Sep 24. Mult Scler Relat Disord. 2020. PMID: 33039944 Free PMC article. Clinical Trial.
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Hartung HP, et al. Among authors: nos c. J Neurol. 2024 Jul;271(7):4348-4360. doi: 10.1007/s00415-024-12326-z. Epub 2024 Apr 22. J Neurol. 2024. PMID: 38649522 Free PMC article. Clinical Trial.
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
Río J, Rovira À, Gasperini C, Tintoré M, Prosperini L, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Midaglia L, Rodriguez-Acevedo B, Zabalza A, Castilló J, Arrambide G, Nos C, Cobo Á, Tur C, Auger C, Sastre-Garriga J, Montalban X. Río J, et al. Among authors: nos c. J Neurol. 2022 Jan;269(1):452-459. doi: 10.1007/s00415-021-10823-z. Epub 2021 Oct 1. J Neurol. 2022. PMID: 34596743
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L, Castilló J, Vidal-Jordana Á, Rodríguez-Acevedo B, Zabalza A, Galán I, Nos C, Salerno A, Auger C, Pareto D, Comabella M, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Montalban X. Tur C, et al. Among authors: nos c. JAMA Neurol. 2023 Feb 1;80(2):151-160. doi: 10.1001/jamaneurol.2022.4655. JAMA Neurol. 2023. PMID: 36534392 Free PMC article.
221 results